Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000078358
Ethics application status
Approved
Date submitted
11/01/2017
Date registered
13/01/2017
Date last updated
5/11/2021
Date data sharing statement initially provided
23/04/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Perampanel for the control of glioma associated seizures – efficacy and safety
Scientific title
Perampanel for the control of glioma associated seizures – efficacy and safety: a pilot phase II randomised controlled trial
Secondary ID [1] 289662 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PEGASUS-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Tumour associated epilepsy 299464 0
Glioma 301616 0
Condition category
Condition code
Neurological 299442 299442 0 0
Epilepsy
Cancer 299443 299443 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The interventional drug to be utilized in this randomized controlled trial is the oral anti-epileptic drug, perampanel. Perampanel is an AMPA-receptor antagonist. Both intervention and comparator (levetiracetam) medications will be identically encapsulated.
Patients with WHO grade II-III supratentorial gliomas will be recruited pre-operatively and receive a 7T MRI scan. Post-operatively, patients will be randomized to receive perampanel or levetiracetam for 52 weeks.
Perampanel will be started at 2mg at night and over the first 4 weeks (escalation phase) will be uptitrated to by 2mg every 2 weeks. At the start of the assessment phase (week 5-52), perampanel will be increased to 6mg. Participants will remain on 6mg daily from week 5 until treatment completion at the end of week 52 unless seizures or side effects occur.

If post-operative seizures develop, perampanel can subsequently undergo 3 uptitrations of 2mg to a maximum of 12mg at night at the discretion of the investigator. If side effects develop and are intolerable, one dose reduction of 2mg can occur.

Participants will have 8 visits following randomisation over the 52-week study period, during which post-operative seizures, compliance and side effects will be assessment by investigators. Participants will be questioned regarding their medication adherence, and tablet/bottle counting will be performed to aid in compliance assessment. Visits will occur at 2, 4, 6, 8 weeks and 4, 6, 9, 12 months.

Intervention code [1] 295289 0
Treatment: Drugs
Comparator / control treatment
The comparator group will receive levetiracetam. Levetiracetam is generally regarded as first line treatment for control of tumour associated seizures, however this is based on limited evidence.
Levetiracetam will be given orally.
Levetiracetam will be started at 250mg twice daily and will be uptitrated to 500mg twice daily after 2 weeks. At the start of the assessment phase assessment phase (week 5-52), Levetiracetam will remain at 500mg twice daily.
Participants will have 8 subsequent visits following randomisation over the 52-week study period, during which post-operative seizures, compliance and side effects will be assessment by investigators. Participants will be questioned regarding their medication adherence, and tablet/bottle counting will be performed to aid in compliance assessment. Visits will occur at 2, 4, 6, 8 weeks and 4, 6, 9, 12 months.
If post-operative seizures develop, Levetiracetam can subsequently undergo up to 3 progressive uptitrations (750mg twice daily, 1000mg twice daily and 1500mg twice daily) at the discretion of the investigator. If side effects develop and are intolerable, one dose reduction to the previous dose can be performed.
Control group
Active

Outcomes
Primary outcome [1] 298925 0
Proportion of patients seizure-free for 24 or more continuous weeks in assessment phase (weeks 5-52) - assessed by seizure diary
Timepoint [1] 298925 0
52 weeks from randomization
Primary outcome [2] 298926 0
Time to first seizure in assessment phase (weeks 5-52) - assessed by seizure diary
Timepoint [2] 298926 0
52 weeks from randomization
Secondary outcome [1] 325657 0
Seizure frequency during assessment phase (weeks 5-52).
Seizures per month (total seizures divided by 11) - assessed by seizure diary
Timepoint [1] 325657 0
52 weeks from randomization
Secondary outcome [2] 325658 0
Proportion of patients who continue on the allocated treatment at 52 weeks
Timepoint [2] 325658 0
52 weeks from randomization
Secondary outcome [3] 325659 0
Proportion of patients who show improvement in QOL (Quality of Life) based on QOLIE-89 scores from baseline to 52 weeks
Improvement defined as baseline score > 52 week score
Timepoint [3] 325659 0
52 weeks from randomization
Secondary outcome [4] 325660 0
Proportion of patients who show improvement in anxiety symptoms (based on HADS score) from baseline to 52 weeks
Improvement defined as baseline score > 52 week score
Timepoint [4] 325660 0
52 weeks from randomization
Secondary outcome [5] 325663 0
Proportion of patients who show improvement in QOL (Quality of Life) based on QOLIE-89 scores from baseline to 16 weeks by treatment group
Improvement defined as baseline score > 16 week score
Timepoint [5] 325663 0
16 weeks from randomization
Secondary outcome [6] 325664 0
Proportion of patients who show improvement in anxiety symptoms (based on HADS score) from baseline to 16 weeks
Improvement defined as baseline score > 16 week score
Timepoint [6] 325664 0
16 weeks from randomization
Secondary outcome [7] 325665 0
Overall survival - time from histological diagnosis to end of follow-up.
Timepoint [7] 325665 0
End of follow-up is 52 weeks after randomization, death or last follow-up if lost to follow-up
Secondary outcome [8] 325666 0
Frequency and type of adverse effects and serious adverse effects - assessed by LAEP questionnaire
Qualitative description of adverse effects which develop over the course of the trial
Timepoint [8] 325666 0
52 weeks from randomization

Eligibility
Key inclusion criteria
Pre-operative phase (ie inclusion for 7T MRI)
1. 18 – 80 years
2. Radiological diagnosis of a supratentorial WHO grade II-III glioma
3. Planned surgical resection or biopsy of lesion
4. 3T MRI performed as clinical standard of care
5. Able to give informed consent
6. Experienced a pre-operative seizure attributed to glioma

Post-operative phase (ie inclusion for treatment intervention)
1. 18-80 years
2. Diagnosis of WHO grade II-III glioma
3. Less than 3 weeks from date of glioma resection or biopsy
4. Experienced a pre-operative seizure attributed to glioma
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Previous non-tumour related neurosurgical procedures (excluding biopsy of glioma)
2. Pre-operative chemotherapy or radiotherapy
3. Receiving >1000mg daily of levetiracetam or multiple concurrent anti-epileptic drugs at time of randomization
4. Contraindication to 7T MRI
5. Significant risk factors for non-tumour associated epilepsy
- Previously diagnosed epilepsy (excluding benign childhood epilepsies)
- Additional epileptogenic intra-cranial pathology (including intra-cranial complications from glioma resection)
6. History of major psychiatric morbidity (such as psychiatric illness requiring hospitalisation or history of psychosis, major depression or suicidality) within the last 2 years
7. Pregnant or breast-feeding
8. Excessive alcohol or recreational drug use

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
allocation concealment by central computer based randomization
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.

Patients will be randomised in a 1:1 fashion, depending upon both the operation (biopsy alone vs larger resection) and WHO grade (II vs III). This will ensure approximately equal numbers of each grade glioma are randomized to each treatment arm in study 1 and 2. A computer generated randomisation method will be utilized with an allocation table uploaded to a Redcap database program. An independent clinical researcher will given access randomise patients using the Redcap database, keeping all other researchers blinded.

Stratifying on the basis of WHO grade will help ensure extra homogeneity between study arms. In study 1 (perampanel vs levetiracetam), patients with one or more pre-operative seizures will be randomised in a 1:1 ratio to either perampanel or levetiracetam. Investigators and patients will be blinded to the assigned treatment until the end of the assessment phase.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This is primarily a hypothesis generating pilot RCT, the results of which will aid study design and power calculations in a subsequent phase III trial. Regardless, power calculations have been performed for planned sample size. Given total sample size of 40, allocation ratio 1:1, two-sided significant level of 0.05, and assumed 65% seizure free rate in patients taking levetiracetam, Fisher’s exact test has power of 0.8 to detect an absolute 33.7% (RR~1.52) increase in seizure free rate. With regards to time to first post-operative seizure analysis, the sample size of 40 patients has 0.8 power to detect a hazard ratio of 0.386, i.e. 38.6% risk of event compared to the control group (placebo or levetiracetam).
Clinicopathological characteristics will be compared on univariate analysis between intervention (perampanel) and comparison groups (levetiracetam). This will be examined using and Fisher’s exact test as appropriate for categorical variables, Independent T-test for continuous, normally distributed variables and Mann-Whiteny U-test for continuous, asymmetric variables. P value <0.05 will indicate a significance difference.
Efficacy to be analysed in both i) intention to treat: randomly assigned to treatment groups and received at least one dose of study treatment and ii) per-protocol: excluded patients who were major protocol violators. Protocol violators will include poor compliance with study drug dosing,

Adaptive statistical analysis:
Adaptive increase in sample size will be performed if the results of interim analysis using data from the first 30 patients in each study are promising as per the methodology of Mehta and Pocock et al. (Statistics in medicine 2011;30:3267-84).. For PEGASUS 1, the maximum sample size will be 162 (n = 81 in each group). Sample size was calculated with two-tailed Fisher's Exact Test, assumes perampanel provides superior outcome, assumes 65% seizure free rate on levetiracetam and is able to detect greater than 20% absolute difference (using 80% power and type 1 error set at alpha 0.05).

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Participant recruitment difficulties
Date of first participant enrolment
Anticipated
12/07/2017
Actual
17/07/2017
Date of last participant enrolment
Anticipated
19/04/2021
Actual
11/11/2019
Date of last data collection
Anticipated
19/04/2022
Actual
11/05/2020
Sample size
Target
40
Accrual to date
Final
11
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 6157 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [2] 6158 0
Melbourne Private Hospital - Parkville
Recruitment hospital [3] 6160 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [4] 7267 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [5] 7268 0
St Vincent's Private Hospital - Fitzroy
Recruitment postcode(s) [1] 13596 0
3050 - Royal Melbourne Hospital
Recruitment postcode(s) [2] 13597 0
3065 - Fitzroy
Recruitment postcode(s) [3] 15033 0
3084 - Heidelberg
Recruitment postcode(s) [4] 15034 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 294051 0
Charities/Societies/Foundations
Name [1] 294051 0
Royal Melbourne Hospital Neuroscience Foundation
Country [1] 294051 0
Australia
Primary sponsor type
Hospital
Name
Melbourne Health
Address
Melbourne Health
Royal Melbourne Hospital
Grattan St
Parkville, Victoria
3050
Country
Australia
Secondary sponsor category [1] 292996 0
None
Name [1] 292996 0
Address [1] 292996 0
Country [1] 292996 0
Other collaborator category [1] 279128 0
University
Name [1] 279128 0
University of Melbourne
Address [1] 279128 0
757 Swanston Street
Parkville, Victoria, 3050
Country [1] 279128 0
Australia
Other collaborator category [2] 279129 0
University
Name [2] 279129 0
University of Pennsylvania
Address [2] 279129 0
University of Pennsylvania
3451 Walnut Street
Philadelphia, PA 19104-6291
Country [2] 279129 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295464 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [1] 295464 0
Ethics committee country [1] 295464 0
Australia
Date submitted for ethics approval [1] 295464 0
31/08/2016
Approval date [1] 295464 0
12/12/2016
Ethics approval number [1] 295464 0
HREC/16/MH/51

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 67378 0
Dr Andrew Neal
Address 67378 0
Melbourne Brain Centre
300 Grattan st
Level 4, Neurosciences
Royal Melbourne Hospital
Parkville, VIC, 3050
Country 67378 0
Australia
Phone 67378 0
+61 3 93427000
Fax 67378 0
Email 67378 0
andrew.neal@unimelb.edu.au
Contact person for public queries
Name 67379 0
Andrew neal
Address 67379 0
Epilepsy Research Office
Level 4, Neurosciences
300 Grattan st
Royal Melbourne Hospital
Parkville, VIC, 3050
Country 67379 0
Australia
Phone 67379 0
+ 61 3 9342 7500
Fax 67379 0
+61 3 93428628
Email 67379 0
andrew.neal@unimelb.edu.au
Contact person for scientific queries
Name 67380 0
Andrew Neal
Address 67380 0
Melbourne Brain Centre
300 Grattan st
Level 4, Neurosciences
Royal Melbourne Hospital
Parkville, VIC, 3050
Country 67380 0
Australia
Phone 67380 0
+61 3 93427000
Fax 67380 0
Email 67380 0
andrew.neal@unimelb.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified data will be made available upon reasonable request from researchers.
When will data be available (start and end dates)?
Available after publication of results. No end date yet determined.
Available to whom?
Researchers from recognised institutions who provide a methodologically sound proposal
Available for what types of analyses?
Only to achieve the aims in the approved proposal
How or where can data be obtained?
Access subject to approvals by Principal Investigator and likely requirement to sign data access agreement


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
13988Study protocol  andrew.neal@unimelb.edu.au
13989Statistical analysis plan  andrew.neal@unimelb.edu.au
13990Informed consent form  andrew.neal@unimelb.edu.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIGlutamate weighted imaging contrast in gliomas with 7?Tesla magnetic resonance imaging2019https://doi.org/10.1016/j.nicl.2019.101694
N.B. These documents automatically identified may not have been verified by the study sponsor.